Infinatas BioPharm Insight to Host New Educational Webinar, Investing in Sunshine: How to Leverage Cloud Computing to Help Meet the New Requirements

Norwood, MA (PRWEB) August 23, 2013

BioPharm Insight will host a new webinar, Investing in Sunshine: How to Leverage Cloud Computing to Help Meet the New Requirements, on Wednesday, August 28, 2013 at 10:00 a.m. EDT. BioPharm Insight, part of Infinata, a Financial Times Group company, is a leading provider of business intelligence solutions which also includes BioPharm Clinical, High Net Worth Insight and wealthmonitor. To register for the webinar, please click here.

The Physician Payments Sunshine Act came into force this month, which requires providers to disclose compensation received from medical industry companies. Pharma, biotech and medical device companies are now required to submit these reports to the Centers for Medicare & Medicaid Services (CMS) on an annual basis. The majority of this information will also be available publicly.

Failure to comply could lead to charges of up to USD 100,000 per incidence.

In a BioPharm Insight article entitled: Sunshine Act open payment requirements to spur cloud-provider growth and M&A interest, experts noted that accurately collecting consistent information could be difficult in todays clinical trial environment as a result of the number of outsourced providers and partners involved in clinical trials. The new legislation could spur growth for cloud providers which enable all parties including sponsors, contract research organisations (CROs) and partners to conveniently upload and access data from anywhere in the world via a virtual network.

In a recent follow-up article, experts told BioPharm Insight the common concerns about sending sensitive clinical and company information into the cloud network and ways providers can allay these fears.

On the webinar, Sunshine Act specialists Tina Fan, director of Acquis Consulting, Tim Immel, Chief Product Officer and Founder of Clinverse and Attorney Sarah Crotts from law firm Womble Carlyle will join BioPharm Insights Natalie Morrison to discuss:

Speak Your Mind

*